Sponsor Dossier
Takeda Pharmaceuticals
Sponsor Dossier for Takeda Pharmaceuticals. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ADCETRIS
- Brand: ADVATE
- Brand: ADYNOVATE
- Brand: ADZYNMA
- Brand: AGRYLIN
- Brand: ALUNBRIG
- Brand: CEPROTIN
- Brand: CINRYZE
- Device (sponsor): Syringe, general-purpose
- Device (sponsor): Medication transfer set
- Device (sponsor): Subcutaneous/intramuscular injection set, medicated
- Device (sponsor): Electric infusion pump administration set
- Device (sponsor): Medicine administration kit, percutaneous, medicated, single-use
- Device (sponsor): General laboratoryware IVDs
- Device (sponsor): Medicine administration kit, percutaneous, medicated, single-use
- Device (sponsor): Syringe, general-purpose
- Device (sponsor): Medicine administration kit, percutaneous, non-medicated, single-use
- Device (sponsor): Medicine administration kit, percutaneous, medicated, single-use
- Device (sponsor): Medicine administration kit, percutaneous, medicated, single-use
- Device (sponsor): Medicine administration kit, percutaneous, medicated, single-use
- Device (sponsor): Medicine administration kit, percutaneous, medicated, single-use
- Device (sponsor): Medicine administration kit, percutaneous, non-medicated, single-use
About
Takeda Pharmaceuticals is an Australian Private Company with ABN 71095610870, registered in NSW. The company is Active and registered for GST from 16 January 2001.
Portfolio
Takeda Pharmaceuticals has 35 brands on the ARTG, of which 34 are indexable and 31 carry a Product Information document. 15 brands are PBS-listed, 18 have a PBAC outcome on record, and 20 have an AusPAR on record. Notable brands include ADCETRIS, ADVATE, ADYNOVATE, ADZYNMA, AGRYLIN, ALUNBRIG, CEPROTIN, CINRYZE, CUVITRU, ENTYVIO, FEIBA-NF, FIRAZYR.
Therapeutic focus
— Haematology: 9 brands — Gastroenterology: 6 brands — Rare Disease: 6 brands — Oncology: 4 brands — Immunology: 3 brands — Psychiatry: 3 brands — Infectious Disease: 2 brands — Renal: 1 brand — Endocrinology: 1 brand
PBS footprint
15 brands are PBS-listed, with the latest PBS schedule date 2026-11-01.
Regulatory activity
The latest PBAC outcome is 2026-07-01, across 18 brands with a PBAC outcome on record. The latest AusPAR is 2026-06-17, across 20 brands with an AusPAR on record.